Beijing Strong Biotechnologies has a Cash Ratio of 4.18. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Beijing Strong Biotechnologies's Cash Ratio or its related term are showing as below:
SZSE:300406'
s Cash Ratio Range Over the Past 10 Years
Min: 0.52 Med: 3.66 Max: 15.1
Current: 4.18
During the past 13 years, Beijing Strong Biotechnologies's highest Cash Ratio was 15.10. The lowest was 0.52. And the median was 3.66.
SZSE:300406's Cash Ratio is ranked better than 85.28% of 231
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.05
vs SZSE:300406: 4.18
Beijing Strong Biotechnologies Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beijing Strong Biotechnologies's Cash Ratio
For the Diagnostics & Research subindustry, Beijing Strong Biotechnologies's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Strong Biotechnologies's Cash Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Beijing Strong Biotechnologies's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Beijing Strong Biotechnologies's Cash Ratio falls into.
Beijing Strong Biotechnologies Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Strong Biotechnologies (SZSE:300406) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Beijing Strong Biotechnologies Cash Ratio Related Terms
Thank you for viewing the detailed overview of Beijing Strong Biotechnologies's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Beijing Strong Biotechnologies (SZSE:300406) Business Description
Beijing Strong Biotechnologies Inc is a China-based provider of in-vitro (IVD) diagnostics products and service. The company is engaged in the research, development, production, and sale of IVD products. It also provides diversified clinical diagnosis solutions to customers. Its products include clinical biochemistry testing, coagulation testing, blood typing, serology and automated blood grouping analyzer. The firm has established a clinical biochemistry platform of the enzymatic method (including enzymatic cycling method), immunoturbidimetric method, and latex immunoturbidimetric method.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300406 has been successfully added to your 